Helia Bio · Cambridge, MA · Est. 2016
Programmable medicine, delivered.
We write medicines in the language your cells already speak — mRNA instructions, wrapped in lipid, that ask the body to make its own therapeutic protein, then quietly clear within days.
The platform
Every program starts as a sequence.
One process, run end to end. We do not rediscover chemistry for each disease — we change the message and keep the machinery. That is why a rare-disease program and a cancer vaccine can share a factory line.
Design the instruction.
We pick a target protein and let the Helia fold engine write the mRNA that codes for it — optimized codon by codon for stability, expression, and a clean immune read.
in silico · 41M conformationsEncapsulate in lipid.
The sequence is wrapped in a proprietary ionizable lipid nanoparticle — the LNP-7 shell — tuned to reach the tissue that needs it, from lymph node to airway epithelium.
LNP-7 · tissue-tropicExpress on site.
Your own cells read the instruction and manufacture the therapeutic protein where it is needed, at native scale — no bioreactor, no purified protein to infuse.
endogenous synthesisClear without a trace.
The mRNA degrades within days and nothing integrates into your genome. The dose ends when the message does — a therapy you can stop, titrate, and repeat.
t½ ≈ 2–5 days · non-integratingThe fold engine
The fold is the medicine.
Between a sequence and a working drug lies the hardest problem in the field — how a chain of amino acids collapses into the one shape that does something. Helia's fold engine simulates that collapse across 41 million conformations before a single base is synthesized, so the molecule we make in the clinic is the molecule we saw on screen.
Clinical pipeline · Q2 2026
Eighteen programs, read as a lab notebook.
Stages shown left→right: discovery, preclinical, Phase 1, Phase 2, Phase 3. Highlighted band marks the current stage.
| Program | Modality | Indication | Stage DISC · PRE · P1 · P2 · P3 |
|---|---|---|---|
| HB-207 | Prophylactic vaccine | Cytomegalovirus Congenital CMV prevention | ▸ Phase 3 · pivotal |
| HB-114 | Individualized neoantigen | Melanoma Adjuvant, post-resection | ▸ Phase 2 · enrolling |
| HB-019 | Self-amplifying RNA | Pan-coronavirus Broad sarbecovirus | ▸ Phase 2 |
| HB-052 | Protein replacement | Propionic acidemia Rare metabolic, pediatric | ▸ Phase 1/2 |
| HB-330 | Tolerizing mRNA | Multiple sclerosis Antigen-specific tolerance | ▸ Phase 1 |
| HB-401 | Inhaled mRNA | Cystic fibrosis ΔF508, nebulized LNP-7 | ▸ Preclinical · IND-enabling |
Modalities on the Helia platform
Evidence, not adjectives
Clinical-stage programs
as of Q2 2026Doses given in trials
across 40 sites, 14 countriesFirst-pass fold accuracy
internal benchmark, n=1,204Sequence to GMP lot
median, individualized programsWork with Helia
Bring us a target. We'll bring the fold.
We partner with academic labs, patient foundations, and pharma on programs where a protein is the answer and time is the constraint. Trial sites and investigators, start here too.
Start a partnership